How Piramal Plans To Scale Up In Critical Care, Build On Acquisitions

Peter DeYoung, CEO of Piramal Critical Care, expects to build “profitable growth positions” from the injectable products acquired from Janssen. He is also upbeat about the commercialization prospects in Europe for intrathecal baclofen and the potential launch of the first desflurane generic in the US.

Peter De'Young
Peter DeYoung, CEO Piramal Critical Care

Piramal Enterprises Ltd. (PEL), the diversified Indian healthcare to financial services group and active M&A participant, plans to deploy a “blended” strategy to expand its critical care business, including in-licensing products in the near-to-medium term.

Peter DeYoung CEO of Piramal Critical Care outlined four key prongs of the company’s growth strategy, including building on the...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip